Neutrophil Extracellular Traps Formation Post-hematopoietic Stem Cell Transplantation
NETs post HSCT
1 other identifier
observational
50
1 country
1
Brief Summary
Identifying the post-transplantation phase wherein neutrophils recover their ability to release NETs could shed new light on the mechanism responsible for the increased susceptibility to infection among these patients and aid in improving their prophylactic antimicrobial treatment. Therefore, we aim to examine neutrophil extracellular traps (NETs) formation, in relation to other neutrophil functions like chemotaxis, superoxide production, hydrogen peroxide production, and the presence of myeloperoxidase, in pediatric patients undergoing autologous and allogeneic hematopoietic stem cell transplantation (HSCT).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Dec 2011
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
December 1, 2011
CompletedFirst Submitted
Initial submission to the registry
December 11, 2011
CompletedFirst Posted
Study publicly available on registry
December 13, 2011
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2014
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2014
CompletedDecember 13, 2011
December 1, 2011
3 years
December 11, 2011
December 12, 2011
Conditions
Keywords
Study Arms (1)
25 autologous/25 allogeneic patients
Eligibility Criteria
Infants, children and adolescents undergoing autologous and allogeneic HSCT at the pediatric hemato-oncology departement of Dana children's Hospital, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel.
You may qualify if:
- All infants, children and adolescents undergoing autologous and allogeneic HSCT at the pediatric hemato-oncology departement of Dana children's Hospital.
You may not qualify if:
- Severe background diseases (like diabetes and lupus) that there is no data in the literature on their influence on NETs production.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Tel-Aviv Sourasky Medical Centerlead
- Max Planck Institute for Infection Biologycollaborator
- Meir Hospital, Kfar Saba, Israelcollaborator
Study Sites (1)
Dana Children's Hospital, Tel-Aviv Sourasky Medical Center
Tel Aviv, 64239, Israel
Biospecimen
10cc of peripheral venous blood will be collected from each patient at several time points: Before transplant, at neutrophil engraftment, 6 weeks, 3 months, 4 months, 6 months, 9 months, 1 year, 1.5 years, 2 years, and 3 years post-transplant, or until normalization of NETs formation in 2 consecutive examinations.
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Sivan Achituv, MD
Tel-Aviv Sourasky Medical Center
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER GOV
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Director, Division of Research and Developement
Study Record Dates
First Submitted
December 11, 2011
First Posted
December 13, 2011
Study Start
December 1, 2011
Primary Completion
December 1, 2014
Study Completion
December 1, 2014
Last Updated
December 13, 2011
Record last verified: 2011-12